New insider activity at Tarsus Pharmaceuticals ( (TARS) ) has taken place on September 10, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director William Phd Link has recently sold 27,116 shares of Tarsus Pharmaceuticals stock, amounting to a total transaction value of $1,545,612.
Spark’s Take on TARS Stock
According to Spark, TipRanks’ AI Analyst, TARS is a Neutral.
Tarsus Pharmaceuticals’ overall stock score is primarily influenced by its strong revenue growth and positive market momentum, as highlighted in the earnings call. However, significant profitability challenges and a negative valuation score due to ongoing losses weigh heavily on the overall score. The technical analysis suggests bullish momentum, but overbought conditions could lead to a pullback. The absence of corporate events in the analysis means the focus remains on financial performance and earnings call insights.
To see Spark’s full report on TARS stock, click here.
More about Tarsus Pharmaceuticals
YTD Price Performance: 2.43%
Average Trading Volume: 645,616
Technical Sentiment Signal: Buy
Current Market Cap: $2.4B